Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Molecular therapeutics advance fight against brain cancer

05.08.2004


An estimated 41,000 new cases of primary brain tumors are expected to be diagnosed in 2004, according to the American Brain Tumor Association. To further narrow the gap between diagnosis and effective therapy, physicians at the University of Pennsylvania Health System now offer several promising approaches to brain tumor treatment, including novel imaging for oncologic neurosurgery and refined genetic testing for tumors to better target treatment.

Through enhanced magnetic resonance imaging (MRI), newer and broader information is helping to better guide tumor removal. MRI is used to measure the anatomy and metabolism of tumors. This informs surgeons pre- and post-operatively with a three-dimensional map of tumor-associated blood flow to more precisely assess the full extent of tumor growth versus conventional imaging methods. "This novel approach helps guide surgery and assessment of treatment response," says Donald M. O’Rourke, M.D., Associate Professor of Neurosurgery. These novel imaging methods are leading to increased patient survival by allowing for greater tumor removal in a safe manner.

Neuroscientists are also ushering in a new era in which genetics will dictate treatment. In the 1990s researchers noted that a more favorable prognosis in patients with certain brain tumors, primarily oligodendrogliomas, was associated with a deletion of genes on chromosomes 1 and 19. This genetic loss translates into a significant life-expectancy gain for some patients and is therefore a robust predictor that post-surgery chemotherapy should be given to such patients.



Patients with the genetic deletion on chromosome 1 have a median survival in certain cases of about 10 years and respond particularly well to chemotherapy given immediately after surgery. Patients with the deletion have slower-growing tumors and show a better response to chemotherapy; whereas, those without the deletion have relatively faster-growing tumors and are less responsive to chemotherapy, so radiation therapy is required sooner. "Given the expected increase in the life-span of patients with this deletion, there is no need to give radiation therapy early in their treatment," explains O’Rourke.

The deletion can only be detected by genetic analysis. "Under the microscope these tumors can look identical, so there’s no way of knowing the difference unless a genetic analysis is performed," explains O’Rourke.

Having the ability to provide such genetic testing to determine treatment is of benefit to patients. "The idea of using a genetic test to predict prognosis and select therapy, thereby deferring potentially deleterious treatment is tremendously attractive," says O’Rourke. "Penn’s genetic testing is done in-house, so patients don’t have to wait for the results." Further, there is no cost to the patient at this point since the tests are performed by the Neuro-oncology Program and supported by the Abramson Cancer Center at Penn. In addition, there is no requirement for additional blood samples, so results will be given more quickly with no need for follow-up visits.

Penn colleagues J. Carl Oberholtzer, MD, PhD, Department of Neuropathology and Myrna Rosenfeld, MD, PhD, Department of Neurology and Director of the Division of Neuro-oncology as well as Jaclyn Biegel, PhD, Director of Cytogenetics, Children’s Hospital of Philadelphia, collaborated with O’Rourke on developing the genetic testing program. Dr. Biegel’s laboratory performs the genetic test and has significant experience with genetic testing of brain tumors.

O’Rourke is also Director of the Human Brain Tumor Tissue Bank at Penn, one of only a few such dedicated banks in the United States. Tissue banks allow for the direct evaluation of human tumors and are one of the best ways to advance treatment options for gliomas and other human cancers. O’Rourke’s basic research interests include finding new treatments for gliomas based on genetic alterations detected in tumors. He is currently investigating a variant of the epidermal growth factor receptor that is present in many primary glioblastomas to better understand the development of malignancy in the brain and how it relates to cancer cell division, survival, and movement.

Karen Kreeger | EurekAlert!
Further information:
http://www.upenn.edu

More articles from Life Sciences:

nachricht Newly designed molecule binds nitrogen
23.02.2018 | Julius-Maximilians-Universität Würzburg

nachricht Atomic Design by Water
23.02.2018 | Max-Planck-Institut für Eisenforschung GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Attoseconds break into atomic interior

A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.

In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...

Im Focus: Good vibrations feel the force

A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.

By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Basque researchers turn light upside down

23.02.2018 | Physics and Astronomy

Finnish research group discovers a new immune system regulator

23.02.2018 | Health and Medicine

Attoseconds break into atomic interior

23.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>